Drug intelligence / Profile preview

CRX

Development stage: Preclinical
Lead developer: Bionor
Modality: Peptides

Overview

CRX is a preclinical peptide drug candidate developed by Bionor Immuno (Bionor Holding AS) for the treatment of HIV infection. It is designed to function as an entry inhibitor by targeting both the CCR5 and CXCR4 co-receptors on CD4+ cells. By blocking the interaction between these co-receptors and the HIV envelope glycoprotein gp120 V3 loop, CRX aims to prevent the virus from entering host cells. CRX is intended to be used as part of a combination therapeutic approach, alongside Bionor's other candidates Vacc-4x and Vacc-C5, to achieve a functional cure for HIV by reducing viral reservoirs and maintaining viral load control without continuous antiretroviral therapy.

Brand names: CRx
Other names: CRX-Bionor ImmunoBionor CRX

Targets

CXCR4 (C-X-C motif chemokine receptor 4)CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on CRX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRX.

Explore the full profile